SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Abdalla SA, Pece-Barbara N, Vera S, Tapia E, Paez E, Bernabeu C, Letarte M. 2000. Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum Mol Genet 9: 12271237.
  • Akiyoshi S, Inoue H, Hanai J-i, Kusanagi K, Nemoto N, Miyazono K, Kawabata M. 1999. c-Ski acts as a transcriptional co-repressor in transforming growth factor-β signaling through interaction with Smads. J Biol Chem 274: 3526935277.
  • Anbazhagan R, Bornman DM, Johnston JC, Westra WH, Gabrielson E. 1999. The S387Y mutations of the transforming growth factor-β receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma. Cancer Res 59: 33633364.
  • Aoki H, Fujii M, Imamura T, Takehara K, Kato M, Miyazono K. 2001. Synergistic effects of different bone morphogenetic protein type I receptors on osteoblast differentiation. J Cell Sci (in press).
  • Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB. 1999. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1: 260266.
  • Bai S, Shi X, Yang X, Cao X. 2000. Smad6 as a transcriptional corepressor. J Biol Chem 275: 82678270.
  • Bamford RN, Roessler E, Burdine RD, Saplakoglu U, dela Cruz J, Splitt M, Towbin J, Bowers P, Marino B, Schier AF, Shen MM, Muenke M, Casey B. 2000. Loss-of-function mutations in the EGF-CFC gene CFC1 are associated with human left-right laterality defects. Nat Genet 26: 365369.
  • Barrett MT, Schutte M, Kern SE, Reid BJ. 1996. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res 56: 43514353.
  • Bartsch D, Hahn SA, Danichevski KD, Ramaswamy A, Bastian D, Galehdari H, Barth P, Schmiegel W, Simon B, Rothmund M. 1999. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 18: 23672371.
  • Belville C, Josso N, Picard JY. 1999. Persistence of Müllerian derivatives in males. Am J Med Genet 89: 218223.
  • Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda T, Miyazono K. 2000. BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol 221: 249258.
  • Bertoldo F, D'Agruma L, Furlan F, Colapietro F, Lorenzi MT, Maiorano N, Iolascon A, Zelante L, Locascio V, Gasparini P. 2000. Transforming growth factor-β1 gene polymorphism, bone turnover, and bone mass in Italian postmenopausal women. J Bone Miner Res 15: 634639.
  • Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth factor β in human disease. N Engl J Med 342: 13501358.
  • Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dube I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE, Housman DE. 1996. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14: 3341.
  • Cazac BB, Roes J. 2000. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13: 443451.
  • Chang H, Huylebroeck D, Verschueren K, Guo Q, Matzuk MM, Zwijsen A. 1999. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development 126: 16311642.
  • Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M. 1997. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 389: 8589.
  • Chen T, Carter D, Garrigue-Antar L, Reiss M. 1998. Transforming growth factor β type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 58: 48054810.
  • Chen YG, Massagué J. 1999. Smad1 recognition and activation by the ALK1 group of transforming growth factor-β family receptors. J Biol Chem 274: 36723677.
  • Datta PK, Moses HL. 2000. STRAP and Smad7 synergize in the inhibition of transforming growth factor-β signaling. Mol Cell Biol 20: 31573167.
  • DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, Kadin ME. 1997. Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 94: 58775881.
  • de Jonge RR, Garrigue-Antar L, Vellucci VF, Reiss M. 1997. Frequent inactivation of the transforming growth factor β type II receptor in small-cell lung carcinoma cells. Oncol Res 9: 8998.
  • Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA. 2000. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67: 737744.
  • DiChiara MR, Kiely JM, Gimbrone MA Jr, Lee ME, Perrella MA, Topper JN. 2000. Inhibition of E-selectin gene expression by transforming growth factor β in endothelial cells involves coactivator integration of Smad and nuclear factor κ B-mediated signals. J Exp Med 192: 695704.
  • Dong C, Li Z, Alvarez R Jr, Feng XH, Goldschmidt-Clermont PJ. 2000. Microtubule binding to Smads may regulate TGFβ activity. Mol Cell 5: 2734.
  • Ebisawa T, Tada K, Kitajima I, Tojo A, Sampath TK, Kawabata M, Miyazono K, Imamura T. 1999. Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 112: 35193527.
  • El-Gamel A, Awad MR, Hasleton PS, Yonan NA, Hutchinson JA, Campbell CS, Rahman AH, Deiraniya AK, Sinnott PJ, Hutchinson IV. 1999. Transforming growth factor-β (TGF-β1) genotype and lung allograft fibrosis. J Heart Lung Transplant 18: 517523.
  • Elvin JA, Yan C, Wang P, Nishimori K, Matzuk MM. 1999. Molecular characterization of the follicle defects in the growth differentiation factor 9-deficient ovary. Mol Endocrinol 13: 10181034.
  • Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L. 1996. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543552.
  • Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. 1992. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80: 18251831.
  • Feng X-H, Derynck R. 1997. A kinase subdomain of transforming growth factor-β (TGF-β) type I receptor determines the TGF-β intracellular signaling specificity. EMBO J 16: 39123923.
  • Feng X-H, Zhang Y, Wu RY, Derynck R. 1998. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-β-induced transcriptional activation. Gene Dev 12: 21532163.
  • Feng X-H, Lin X, Derynck R. 2000. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15Ink4B transcription in response to TGF-β. EMBO J 19: 51785193.
  • Francis-West PH, Abdelfattah A, Chen P, Allen C, Parish J, Ladher R, Allen S, MacPherson S, Luyten FP, Archer CW. 1999. Mechanisms of GDF-5 action during skeletal development. Development 126: 13051315.
  • Galloway SM, McNatty KP, Cambridge LM, Laitinen MP, Juengel JL, Jokiranta TS, McLaren RJ, Luiro K, Dodds KG, Montgomery GW, Beattie AE, Davis GH, Ritvos O. 2000. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet 25: 279283.
  • Germain S, Howell M, Esslemont GM, Hill CS. 2000. Homeodomain and winged-helix transcription factors recruit activated Smads to distinct promoter elements via a common Smad interaction motif. Gene Dev 14: 435451.
  • Gilboa L, Nohe A, Geissendorfer T, Sebald W, Henis YI, Knaus P. 2000. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell 11: 10231035.
  • Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. 1998. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 58: 53295332.
  • Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 92: 49174921.
  • Gong Y, Krakow D, Marcelino J, Wilkin D, Chitayat D, Babul-Hirji R, Hudgins L, Cremers CW, Cremers FP, Brunner HG, Reinker K, Rimoin DL, Cohn DH, Goodman FR, Reardon W, Patton M, Francomano CA, Warman ML. 1999. Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. Nat Genet 21: 302304.
  • Gouédard L, Chen Y-G, Thevenet L, Racine C, Borie S, Lamarre I, Josso N, Massagué J, di Clemente N. 2000. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. J Biol Chem 275: 2797327978.
  • Gripp KW, Wotton D, Edwards MC, Roessler E, Ades L, Meinecke P, Richieri-Costa A, Zackai EH, Massague J, Muenke M, Elledge SJ. 2000. Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination. Nat Genet 25: 205208.
  • Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R, Georges M. 1997. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 17: 7174.
  • Gu Z, Reynolds EM, Song J, Lei H, Feijen A, Yu L, He W, MacLaughlin DT, van den Eijnden-van Raaij J, Donahoe PK, Li E. 1999. The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. Development 126: 25512561.
  • Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE. 1996a. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 56: 490494.
  • Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. 1996b. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350353.
  • Hanai J-i, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K, Ito Y. 1999. Interaction and functional cooperation of PEBP2/CBF with Smads: Synergistic induction of the immunoglobulin germline Cα promoter. J Biol Chem 274: 3157731582.
  • Hata A, Seoane J, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massagué J. 2000. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell 100: 229240.
  • Heldin C-H, Miyazono K, ten Dijke P. 1997. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465471.
  • Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sistonen P, Tomlinson IP, Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA. 1998. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280: 10861088.
  • Hua X, Miller ZA, Wu G, Shi Y, Lodish HF. 1999. Specificity in transforming growth factor β-induced transcription of the plasminogen activator inhibitor-1 gene: interactions of promoter DNA, transcription factor μ E3, and Smad proteins. Proc Natl Acad Sci USA 96: 1313013135.
  • Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, Ohki M, Hayashi Y. 1997. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood 90: 46994704.
  • Ishikawa T, Yoshioka H, Ohuchi H, Noji S, Nohno T. 1995. Truncated type II receptor for BMP-4 induces secondary axial structures in Xenopus embryos. Biochem Biophys Res Commun 216: 2633.
  • Ito Y. 1999. Molecular basis of tissue-specific gene expression mediated by the Runt domain transcription factor PEBP2/CBF. Genes Cells 4: 685696.
  • Itoh S, Ericsson J, Nishikawa J, Heldin C-H, ten Dijke P. 2000. The transcriptional co-activator P/CAF potentiates TGF-β/Smad signaling. Nucleic Acids Res 28: 42914298.
  • Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Tomita N, Ohue M, Hayakawa T. 1997. Microsatellite instability and mutated type II transforming growth factor-β receptor gene in gliomas. Cancer Lett 112: 251256.
  • Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massagué J, Nimer SD. 2000. Inhibition of the transforming growth factor β1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 275: 4028240287.
  • Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, Lissens W, Van Maldergem L, Vanhoenacker F, Verbruggen L, Van Hul W. 2000. Mutations in the gene encoding the latency-associated peptide of TGF- β1 cause Camurati-Engelmann disease. Nat Genet 26: 273275.
  • Jiang Y, Liang H, Guo W, Kottickal LV, Nagarajan L. 2000. Differential expression of a novel C-terminally truncated splice form of SMAD5 in hematopoietic stem cells and leukemia. Blood 95: 39453950.
  • Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA. 1996. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13: 189195.
  • Kang Y, Reddi AH. 1996. Identification and cloning of a novel type I serine/threonine kinase receptor of the TGF-β/BMP superfamily in rat prostate. Biochem Mol Biol Int 40: 9931001.
  • Kang SH, Won K, Chung HW, Jong HS, Song YS, Kim SJ, Bang YJ, Kim NK. 1998. Genetic integrity of transforming growth factor β (TGF-β) receptors in cervical carcinoma cell lines: loss of growth sensitivity but conserved transcriptional response to TGF-β. Int J Cancer 77: 620625.
  • Kardassis D, Pardali K, Zannis VI. 2000. Smad proteins transactivate the human ApoCIII promoter by interacting physically and functionally with hepatocyte nuclear factor 4. J Biol Chem 275: 4140541414.
  • Kawabata M, Miyazono K. 2000. Bone morphogenetic proteins. In: CanalisE, editor. Skeletal Growth Factors. Philadelphia: Lippincott Williams & Wikins. p 269290.
  • Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. 1996a. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2: 12551261.
  • Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M, Lee C. 1996b. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res 56: 4448.
  • Kim RH, Wang D, Tsang M, Martin J, Huff C, de Caestecker MP, Parks WT, Meng X, Lechleider RJ, Wang T, Roberts AB. 2000. A novel Smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-β signal transduction. Gene Dev 14: 16051616.
  • Kimura N, Matsuo R, Shibuya H, Nakashima K, Taga T. 2000. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 275: 1764717652.
  • Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, Yamada K, Kondo S, Ikegawa S, Nishimura G, Fukushima Y, Nakagomi T, Saito H, Sugimoto T, Kamegaya M, Hisa K, Murray JC, Taniguchi N, Niikawa N, Yoshiura K-i. 2000. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet 26: 1920.
  • Knaus PI, Lindemann D, DeCoteau JF, Perlman R, Yankelev H, Hille M, Kadin ME, Lodish HF. 1996. A dominant inhibitory mutant of the type II transforming growth factor β receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 16: 34803489.
  • Kosaki K, Bassi MT, Kosaki R, Lewin M, Belmont J, Schauer G, Casey B. 1999. Characterization and mutation analysis of human LEFTY A and LEFTY B, homologues of murine genes implicated in left-right axis development. Am J Hum Genet 64: 712721.
  • Kosaki R, Gebbia M, Kosaki K, Lewin M, Bowers P, Towbin JA, Casey B. 1999. Left-right axis malformations associated with mutations in ACVR2B, the gene for human activin receptor type IIB. Am J Med Genet 82: 7076.
  • Kretzschmar M, Doody J, Timokhina I, Massagué J. 1999. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev 13: 804816.
  • Kumar A, Novoselov V, Celeste AJ, Wolfman NM, ten Dijke P, Kuehn MR. 2001. Nodal signaling utilizes activin/TGF-β receptor regulated Smads. J Biol Chem 276: 656661.
  • Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H. 1998. The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3. Nature 394: 9296.
  • Labbé E, Silvestri C, Hoodless PA, Wrana JL, Attisano L. 1998. Smad2 and Smad3 positively and negatively regulate TGFβ-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell 2: 109120.
  • Labbé E, Letamendia A, Attisano L. 2000. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-β and Wnt pathways. Proc Natl Acad Sci USA 97: 83588363.
  • Lane KB, Machado RD, Pauciulo MW, Thomson JR, Philips JA, Loyd JE, Nichols WC, Trembath RC. 2000. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet 26: 8184.
  • Lau AL, Kumar TR, Nishimori K, Bonadio J, Matzuk MM. 2000. Activin βC and βE genes are not essential for mouse liver growth, differentiation, and regeneration. Mol Cell Biol 20: 61276137.
  • Lebrun JJ, Vale WW. 1997. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. Mol Cell Biol 17: 16821691.
  • Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, Wozney JM, Kim EG, Choi JY, Ryoo HM, Bae SC. 2000. Runx2 is a common target of transforming growth factor β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 20: 87838792.
  • Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W. 2000. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404: 411414.
  • Li B, Khanna A, Sharma V, Singh T, Suthanthiran M, August P. 1999. TGF-β1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 33: 271275.
  • Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP. 1999. Defective angiogenesis in mice lacking endoglin. Science 284: 15341537.
  • Lin X, Liang M, Feng X-H. 2000. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in TGF-β signaling. J Biol Chem 275: 3681836822.
  • Liu F, Massagué J, Ruiz i Altaba A. 1998. Carboxy-terminally truncated Gli3 proteins associate with Smads. Nat Genet 20: 325326.
  • Liu X, Elia AEH, Law SF, Golemis EA, Farley J, Wang T. 2000. A novel ability of Smad3 to regulate proteasomal degradation of a Cas family member HEF1. EMBO J 19: 67596769.
  • Lopez-Rovira T, Chalaux E, Rosa JL, Bartrons R, Ventura F. 2000. Interaction and functional cooperation of NFkB with Smads. J Biol Chem 275: 2893728946.
  • Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, Zhou Q. 1999. The Ski oncoprotein interacts with the Smad proteins to repress TGFβ signaling. Gene Dev 13: 21962206.
  • Luyten FP, Kaplan FS, Shore EM. 2000. Clinical disorders associated with bone morphogenetic proteins In: CanalisE, editor. Skeletal Growth Factors. Philadelphia: Lippincott Williams & Wikins. p 323334.
  • MacGrogan D, Pegram M, Slamon D, Bookstein R. 1997. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 15: 11111114.
  • Macías-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL. 1998. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem 273: 2562825636.
  • Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al. 1995. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 13361338.
  • Massagué J. 1998. TGF-β signal transduction. Annu Rev Biochem 67: 753791.
  • Massagué J, Blain SW, Lo RS. 2000. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103: 295309.
  • Massagué J, Chen Y-G. 2000. Controlling TGF-β signaling. Genes Dev 14: 627644.
  • McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J. et al. 1994. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8: 345351.
  • McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, Weksler BB, Sanborn TA, Bergman G, Bush HL Jr. 1997. Genomic instability in the type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 100: 21822188.
  • McPherron AC, Lee SJ. 1997. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94: 1245712461.
  • McPherron AC, Lawler AM, Lee SJ. 1997. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387: 8390.
  • Melhuish TA, Wotton D. 2000. The intraction of the carboxy terminus-binding protein with the Smad corepressor TGIF is disrupted by a holoprosencephaly mutation in TGIF. J Biol Chem 275: 3976239766.
  • Meno C, Gritsman K, Ohishi S, Ohfuji Y, Heckscher E, Mochida K, Shimono A, Kondoh H, Talbot WS, Robertson EJ, et al. 1999. Mouse Lefty2 and zebrafish antivin are feedback inhibitors of Nodal signaling during vertebrate gastrulation. Mol Cell 4: 287298.
  • Miura S, Takeshita T, Asao H, Kimura Y, Murata K, Sasaki Y, Hanai J-i, Beppu H, Tsukazaki T, Wrana JL, Miyazono K, Sugamura K. 2000. Hgs (Hrs), a FYVE domain protein, is involved in Smad signaling through cooperation with SARA. Mol Cell Biol 20: 93469355.
  • Miyazono K, ten Dijke P, Ichijo H, Heldin C-H. 1994. Receptors for transforming growth factor-β. Adv Immunol 55: 181220.
  • Miyazono K. 2000. Positive and negative regulation of TGF-β signaling. J Cell Sci 113: 11011109.
  • Miyazono K, ten Dijke P, Heldin C-H. 2000. TGF-β signaling by Smad proteins. Adv Immunol 75: 115157.
  • Miyazono K. 2001. Bone morphogenetic protein receptors and actions. In: BilezikianJP, RaiszLG, RodinG, editors. Principles of Bone Biology, 2nd ed: San Diego Academic Press. (in press).
  • Mulder KM. 2000. Role of Ras and Mapks in TGFβ signaling. Cytokines Growth Factor Rev 11: 2335.
  • Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, et al. 1995. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55: 55455547.
  • Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi T, Saji S, Shimokata K, Takahashi T, Takahashi T. 1996. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 56: 27182720.
  • Nakamura K, Shirai T, Morishita S, Uchida S, Saeki-Miura K, Makishima F. 1999. p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. Exp Cell Res 250: 351363.
  • Nakaoka T, Gonda K, Ogita T, Otawara-Hamamoto Y, Okabe F, Harii K, Miyazono K, Takuwa Y, Fujita T. 1997. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 100: 28242832.
  • Nakashima K, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Kawabata M, Miyazono K, Taga T. 1999. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 284: 479482.
  • Nishihara A, Hanai J-i, Okamoto N, Yanagisawa J, Kato S, Miyazono K, Kawabata M. 1998. Role of p300, a transcriptional coactivator, in signalling of TGF-β. Genes Cells 3: 613623.
  • Nishihara A, Hanai J-i, Imamura T, Miyazono K, Kawabata M. 1999. E1A inhibits transforming growth factor-β signaling through binding to Smad proteins. J Biol Chem 274: 2871628723.
  • Nishita M, Hashimoto MK, Ogata S, Laurent MN, Ueno N, Shibuya H, Cho KWY. 2000. Interaction between Wnt and TGF-β signalling pathways during formation of Spemann's organizer. Nature 403: 781785.
  • Nishitoh H, Ichijo H, Kimura M, Matsumoto T, Makishima F, Yamaguchi A, Yamashita H, Enomoto S, Miyazono K. 1996. Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem 271: 2134521352.
  • Nishizuka S, Tamura G, Maesawa C, Sakata K, Suzuki Y, Iwaya T, Terashima M, Saito K, Satodate R. 1997. Analysis of the DPC4 gene in gastric carcinoma. Jpn J Cancer Res 88: 335339.
  • Nomura M, Li E. 1998. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 393: 786790.
  • Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D, Pedersen-Bjergaard J, Parganas E, Ihle JN, Rowley JD. 1994. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci USA 91: 40044008.
  • Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E. 2000. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97: 26262631.
  • Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massagué J, Niehrs C. 1999. Silencing of TGF-β signalling by the pseudoreceptor BAMBI. Nature 401: 480485.
  • Pardali E, Xie XQ, Tsapogas P, Itoh S, Arvanitidis K, Heldin C-H, ten Dijke P, Grundstrom T, Sideras P. 2000. Smad and AML proteins synergistically confer transforming growth factor β1 responsiveness to human germ-line IgA genes. J Biol Chem 275: 35523560.
  • Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D, Moustakas A. 2000. Role of Smad proteins and transcription factor Sp1 in p21Waf-1/Cip-1. J Biol Chem 275: 2924429256.
  • Pece-Barbara N, Cymerman U, Vera S, Marchuk DA, Letarte M. 1999. Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet 8: 21712181.
  • Pekarsky Y, Rynditch A, Wieser R, Fonatsch C, Gardiner K. 1997. Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia. Cancer Res 57: 39143919.
  • Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, et al. 1995. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376: 348351.
  • Polinkovsky A, Robin NH, Thomas JT, Irons M, Lynn A, Goodman FR, Reardon W, Kant SG, Brunner HG, van der Burgt I, Chitayat D, McGaughran J, Donnai D, Luyten FP, Warman ML. 1997. Mutations in CDMP1 cause autosomal dominant brachydactyly type C. Nat Genet 17: 1819.
  • Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL, Dastugue N, Macintyre E, Denis C, Bauters F, Kerckaert JP, Cosson A, Fenaux P. 2000. High incidence of biallelic point mutations in the runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 96: 28622869.
  • Reddi AH. 1998. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 16: 247252.
  • Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA. 1995. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85: 36623670.
  • Roberts AB, Sporn MB. 1990. The transforming growth factor-βs. In: SpornMB, RobertsAB, editors. Peptide Growth Factors and Their Receptors part I. Berlin: Springer-Verlag. p 419472.
  • Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, Heldin C-H, Miyazono K. 1995. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA 92: 76327636.
  • Ryden M, Imamura T, Jornvall H, Belluardo N, Neveu I, Trupp M, Okadome T, ten Dijke P, Ibanez CF. 1996. A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous system. J Biol Chem 271: 3060330609.
  • Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S. 1999. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling. J Biol Chem 274: 89498957.
  • Scherer A, Graff JM. 2000. Calmodulin differentially modulates Smad1 and Smad2 signaling. J Biol Chem 275: 4143041438.
  • Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. 1999. A deletion in the gene for transforming growth factor β type I receptor abolishes growth regulation by transforming growth factor β in a cutaneous T-cell lymphoma. Blood 94: 28542861.
  • Schutte M. 1999. DPC4/SMAD4 gene alterations in human cancer, and their functional implications. Ann Oncol 10 (Suppl 4): 5659.
  • Shen MM, Schier AF. 2000. The EGF-CFC gene family in vertebrate development. Trends Genet 16: 303309.
  • Shi X, Yang X, Chen D, Chang Z, Cao X. 1999. Smad1 interacts with homeobox DNA-binding proteins in bone morphogenetic protein signaling. J Biol Chem 274: 1371113717.
  • Shi X, Bai S, Li L, Cao X. 2001. Hoxa-9 represses TGF-β-induced osteopontin gene transcription. J Biol Chem 276: 850885.
  • Shimizu A, Kato M, Nakao A, Imamura T, ten Dijke P, Heldin C-H, Kawabata M, Shimada S, Miyazono K. 1998. Identification of receptors and Smad proteins involved in activin signaling in a human epidermal keratinocyte cell line. Genes Cells 3: 125134.
  • Song CZ, Tian X, Gelehrter TD. 1999. Glucocorticoid receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci USA 96: 1177611781.
  • Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG. 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23: 166175.
  • Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. 1999. Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein. Science 286: 771774.
  • Sun Y, Liu X, Ng-Eaton E, Lane WS, Lodish HF, Weinberg RA. 1999a. Interaction of the Ski oncoprotein with Smad3 regulates TGF-β signaling. Mol Cell 4: 499509.
  • Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. 1999b. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor-β signaling. Proc Natl Acad Sci USA 96: 1244212447.
  • Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, August P. 2000. Transforming growth factor-β1 hyperexpression in African-American hypertensives: A novel mediator of hyper tension and/or target organ damage. Proc Natl Acad Sci USA 97: 34793484.
  • Suzukawa K, Kodera T, Shimizu S, Nagasawa T, Asou H, Kamada N, Taniwaki M, Yokota J, Morishita K. 1999. Activation of EVI1 transcripts with chromosomal translocation joining the TCRVβ locus and the EVI1 gene in human acute undifferentiated leukemia cell line (Kasumi-3) with a complex translocation of der(3)t(3;7;8). Leukemia 13: 13591366.
  • Takakura S, Okamoto A, Saito M, Yasuhara T, Shinozaki H, Isonishi S, Yoshimura T, Ohtake Y, Ochiai K, Tanaka T. 1999. Allelic imbalance in chromosome band 18q21 and SMAD4 mutations in ovarian cancers. Genes Chromosomes Cancer 24: 264271.
  • Taki T, Sako M, Tsuchida M, Hayashi Y. 1997. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 89: 39453950.
  • Tanaka S, Mori M, Mafune K, Ohno S, Sugimachi K. 2000. A dominant negative mutation of transforming growth factor-β receptor type II gene in microsatellite stable oesophageal carcinoma. Br J Cancer 82: 15571560.
  • ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, Ichijo H, Heldin C-H, Miyazono K. 1994. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 269: 1698516988.
  • Thisse C, Thisse B. 1999. Antivin, a novel and divergent member of the TGFβ superfamily, negatively regulates mesoderm induction. Development 126: 229240.
  • Thomas JT, Lin K, Nandedkar M, Camargo M, Cervenka J, Luyten FP. 1996. A human chondrodysplasia due to a mutation in a TGF-β superfamily member. Nat Genet 12: 315317.
  • Thomas JT, Kilpatrick MW, Lin K, Erlacher L, Lembessis P, Costa T, Tsipouras P, Luyten FP. 1997. Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1. Nat Genet 17: 5864.
  • Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J, Kambadur R. 2000. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 275: 4023540243.
  • Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC. 2000. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet 37: 741745.
  • Togo G, Toda N, Kanai F, Kato N, Shiratori Y, Kishi K, Imazeki F, Makuuchi M, Omata M. 1996. A transforming growth factor β type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. Cancer Res 56: 56205623.
  • Tsuchida K, Sawchenko PE, Nishikawa S, Vale WW. 1996. Molecular cloning of a novel type I receptor serine/threonine kinase for the TGF-β superfamily from rat brain. Mol Cell Neurosci 7: 467478.
  • Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. 1998. SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor. Cell 95: 779791.
  • Uchida K, Nagatake M, Osada H, Yatabe Y, Kondo M, Mitsudomi T, Masuda A, Takahashi T, Takahashi T. 1996. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res 56: 55835585.
  • Urano T, Yashiroda H, Muraoka M, Tanaka K, Hosoi T, Inoue S, Ouchi Y, Tanaka K, Toyoshima H. 1999. p57Kip2 is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor β1. J Biol Chem 274: 1219712200.
  • Urness LD, Sorensen LK, Li DY. 2000. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26: 328331.
  • Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P, Nelles L, Wuytens G, Su MT, Bodmer R, Smith JC, Huylebroeck D. 1999. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes. J Biol Chem 274: 2048920498.
  • Vincent F, Hagiwara K, Ke Y, Stoner GD, Demetrick DJ, Bennett WP. 1996. Mutation analysis of the transforming growth factor β type II receptor in sporadic human cancers of the pancreas, liver, and breast. Biochem Biophys Res Commun 223: 561564.
  • Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ. 1998. Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. Cell 92: 797808.
  • Wang D, Kanuma T, Mizunuma H, Takama F, Ibuki Y, Wake N, Mogi A, Shitara Y, Takenoshita S. 2000. Analysis of specific gene mutations in the transforming growth factor-β signal transduction pathway in human ovarian cancer. Cancer Res 60: 45074512.
  • Woodford-Richens K, Williamson J, Bevan S, Young J, Leggett B, Frayling I, Thway Y, Hodgson S, Kim JC, Iwama T, Novelli M, Sheer D, Poulsom R, Wright N, Houlston R, Tomlinson I. 2000. Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epithelium. Cancer Res 60: 24772482.
  • Wotton D, Lo RS, Lee S, Massagué J. 1999. A Smad transcriptional corepressor. Cell 97: 2339.
  • Xiao Z, Liu X, Lodish HF. 2000. Importin β mediates nuclear translocation of Smad3. J Biol Chem 275: 2342523428.
  • Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K. 1999. Alternatively spliced variant of Smad2 lacking exon 3: Comparison with wild-type Smad2 and Smad3. J Biol Chem 274: 703709.
  • Yahata T, de Caestecker MP, Lechleider RJ, Andriole S, Roberts AB, Isselbacher KJ, Shioda T. 2000. The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors. J Biol Chem 275: 88258834.
  • Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. 1999. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 18: 48794883.
  • Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, Hase M, Takai H, Harada A, Ikeda K. 1998. Association of a polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 13: 15691576.
  • Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, Kato S. 1999. Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283: 13171321.
  • Yang X, Castilla LH, Xu X, Li C, Gotay J, Weinstein M, Liu PP, Deng CX. 1999. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development 126: 15711580.
  • Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. 2000. Association of a T29[RIGHTWARDS ARROW]C polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101: 27832787.
  • Yoshida Y, Tanaka S, Umemori H, Minowa M, Usui M, Ikematsu N, Hosoda E, Imamura T, Kuno J, Yamashita T, Miyazono K, Noda M, Noda T, Yamamoto T. 2000. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103: 10851097.
  • Zhang Y, Feng X-H, Derynck R. 1998. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature 394: 909913.
  • Zhang Y, Derynck R. 2000. Transcriptional regulation of the transforming growth factor-β-inducible mouse germ line Ig α constant region gene by functional cooperation of Smad, CREB, and AML family members. J Biol Chem 275: 1697916985.
  • Zhang YW, Yasui N, Ito K, Huang G, Fujii M, Hanai J-i, Nogami H, Ochi T, Miyazono K, Ito Y. 2000. A RUNX2/PEBP2αA/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci USA 97: 1054910554.
  • Zhou G, Chen Y, Zhou L, Thirunavukkarasu K, Hecht J, Chitayat D, Gelb BD, Pirinen S, Berry SA, Greenberg CR, Karsenty G, Lee B. 1999. CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. Hum Mol Genet 8: 23112316.
  • Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. 1999. A SMAD ubiquitin ligase targerts the BMP pathway and affects embryonic pattern formation. Nature 400: 687693.